Kowa Pharmaceuticals America Inc. today announced publication of results of the INTREPID Trial (HIV-infected patieNts and TREatment with PItavastatin vs. pravastatin for Dyslipidemia) in The Lancet HIV. Results of the Phase 4 trial showed that LIVALO (pitavastatin) 4 mg was superior to pravastatin 40 mg in reducing LDL cholesterol (LDL-C) in adults with HIV and dyslipidemia and had a comparable safety profile.
Puma Biotechnology Inc. announced that the U.S. Food and Drug Administration scheduled the New Drug Application (NDA) for neratinib for discussion by the Oncologic Drugs Advisory Committee on May 24, 2017. Neratinib is an investigational therapy for the extended adjuvant treatment of early stage HER2-positive breast cancer that has previously been treated with a trastuzumab containing regimen.
Bristol-Myers Squibb Company and Nordic Bioscience, a Danish company specializing in biomarker technologies, today announced a collaboration agreement to develop biomarker technology to potentially aid in the diagnosis and monitoring of fibrotic diseases including non-alcoholic steatohepatitis (NASH).
Introducing mobile into the patient engagement journey is one way that brands can drive efficiencies across three key areas.
Zoetis Inc. and Nexvet Biopharma plc announced an agreement. Zoetis, through a wholly owned subsidiary (Zoetis Bidco), will purchase Nexvet, an innovator in monoclonal antibody therapies for companion animals, for a purchase price of US$6.72 per share, representing an aggregate equity valuation of approximately $85 million.
Icon Bioscience Inc., a specialty biopharmaceutical company focused on utilizing its Verisome drug-delivery platform to develop unique intraocular eye-care therapeutics, announced the submission of a New Drug Application (NDA) to the United States Food and Drug Administration for the company’s lead pipeline product Dexycu (IBI-10090).
NextGen Healthcare Information Systems LLC, a wholly owned subsidiary of Quality Systems Inc., announced an agreement to acquire Entrada Inc.
Pancreatic Cancer Action Network (PanCAN) grantee George Miller, MD, and his research team at NYU Langone Medical Center discovered a novel and potentially targetable way that pancreatic cancer cells hide themselves from the immune system. The findings, published in the journal Nature Medicine, have the potential to broach a new era of effective immunotherapies for pancreatic cancer.
The U.S. FDA approved supplemental indications for Gilead Sciences’ Harvoni (ledipasvir 90 mg/sofosbuvir 400 mg) tablets and Sovaldi (sofosbuvir 400 mg) tablets.
Less than a year after its launch, Consulting at McCann Health is expanding its client roster with further projects from big-6 Pharma community.
